Sarepta Plunges After FDA Advisers Don't Back DMD Drug

Updated on
  • Panel voted 7-3 that muscle drug wasn't shown to be effective
  • Shares fall 26 percent following Monday's FDA meeting

Sarepta Therapeutics Inc. plummeted Tuesday after it failed to win the backing of a panel of U.S. regulatory advisers for its experimental drug to treat a devastating muscle disease called Duchenne muscular dystrophy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.